Pipeline A robust pipeline to treat the most resistant cancers Diverse tumors demand a diverse arsenal of therapeutic approaches. From monoclonal and bispecific antibodies, to antibody drug conjugates, to CAR T-cell therapies, discover what we have in development. CTLA-4 Preclinical IND-enabling Phase 1 Phase 2 Phase 3 Next Milestone Worldwide Rights gotistobart(ONC-392) 2L IO-resistant NSCLC Preclinical IND-enabling Phase 1 Phase 2 Phase 3 Enrollment completion 1H 2025 gotistobart(ONC-392)* Advanced solid tumors Preclinical IND-enabling Phase 1 Phase 2 Phase 3 ±pembrolizumab* Enrollment completion 1H 2024 AI-061, PD-1coformulation Solid tumors Preclinical IND-enabling Phase 1 Phase 2 Phase 3 Ph 1 completion 1H 2024 *In partnership with SIGLEC Preclinical IND-enabling Phase 1 Phase 2 Phase 3 Next Milestone Worldwide Rights AI-071 Immune-related adverse events Preclinical IND-enabling Phase 1 Phase 2 Phase 3 Ph 2 initiation 2H 2024 ONC-841 Solid tumors Preclinical IND-enabling Phase 1 Phase 2 Phase 3 Ph 1 initiation 2H 2024 CD24 Preclinical IND-enabling Phase 1 Phase 2 Phase 3 Next Milestone Worldwide Rights ONC-782 Solid and hematologic malignancies Preclinical IND-enabling Phase 1 Phase 2 Phase 3 IND enabling studies Q1 2024 ONC-783 Hematologic malignancies Preclinical IND-enabling Phase 1 Phase 2 Phase 3 IND enabling studies Q1 2024 ONC-784 Oncology Preclinical IND-enabling Phase 1 Phase 2 Phase 3 IND enabling studies Q1 2024 Clinical trials recruiting now We are currently recruiting patients for 4 clinical trials in a range of indications. If you or someone you care about is battling cancer, we welcome you to learn more and get in touch. PRESERVE-009An open-label phase 1 study on the safety, pharmacokinetics, and efficacy of AI-061 in advanced solid tumorsIndications: melanoma, non–small cell lung cancer, head and neck squamous cell carcinoma, high-grade serous adenocarcinoma of the ovary, primary peritoneal carcinoma, fallopian tube cancer, endometrial cancer, cervical cancer, renal cell carcinoma, bladder cancer, esophageal cancer, gastric cancer, anal cancer, hepatocellular carcinoma, bile duct cancer Learn more PRESERVE-004A Phase 2 study that compares two doses of gotistobart in combination with a fixed dose of pembrolizumabIndications: Platinum-resistant ovarian cancer Learn more PRESERVE-001A Phase 1 open-label study of gotistobart as a monotherapy and in combination with PembrolizumabIndications: Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cance, Ovarian Cance, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction adenocarcinoma, Cervical Cancer, AAdenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma Learn more PRESERVE-006A Phase 2 study examining the safety and efficacy of gotistobart in combination with lutetium Lu 177 vipivotide tetraxetanIndications: Metastatic Castration-resistant Prostate Cancer Learn more PRESERVE-003A Phase 3 study of gotistobart versus docetaxelIndications: Non-Small Cell Lung Cancers that Progressed on PD-1/PD-l1 Inhibitors Learn more ONC-841-002Safety, Pharmacokinetics (PK) and Efficacy of ONC-841 in Advanced Solid Tumors NCT06352359Indications: Advanced or metastatic cancers Learn more Clinical trials recruiting soon For further inquiries about our clinical trials, don’t hesitate to reach out. Contact us